NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $91.08 -0.06 (-0.07%) As of 03:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About ANI Pharmaceuticals Stock (NASDAQ:ANIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$90.79▼$92.5350-Day Range$62.56▼$91.1452-Week Range$52.50▼$92.53Volume190,591 shsAverage Volume372,150 shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/APrice Target$84.75Consensus RatingBuy Company Overview ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 63% of companies evaluated by MarketBeat, and ranked 405th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.07% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.07% in the coming year, from $3.86 to $4.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is -118.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is -118.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.48% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 3.76%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.3 / 5Environmental Score-2.48 Percentage of Shares Shorted11.48% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 3.76%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.26 News SentimentANI Pharmaceuticals has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for ANI Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest12 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,264,427.00 in company stock.Percentage Held by Insiders11.10% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIP Stock News HeadlinesANI Pharmaceuticals (NASDAQ:ANIP) Director Antonio Pera Sells 5,421 SharesAugust 21 at 8:00 AM | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Sells $611,635.29 in StockAugust 19 at 4:27 AM | insidertrades.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 22 at 2:00 AM | Brownstone Research (Ad)ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 SharesAugust 15, 2025 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 52,990 SharesAugust 21 at 4:19 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) COO Sells $4,206,454.80 in StockAugust 21 at 4:19 AM | americanbankingnews.comQ2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals SegmentAugust 20 at 1:00 PM | msn.com3 Healthcare Stocks We’re Skeptical OfAugust 18, 2025 | finance.yahoo.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $55.28 at the beginning of 2025. Since then, ANIP shares have increased by 65.1% and is now trading at $91.2520. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its earnings results on Friday, August, 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The company's quarterly revenue was up 53.2% compared to the same quarter last year. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional investors include Global Alpha Capital Management Ltd. (3.98%), Ranger Investment Management L.P. (2.46%), William Blair Investment Management LLC (2.26%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Patrick D Walsh, Krista Davis, Thomas Andrew Rowland, Thomas Haughey, Antonio R Pera, Jeanne Thoma, Renee P Tannenbaum and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/08/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees600Year FoundedN/APrice Target and Rating Average Price Target for ANI Pharmaceuticals$84.75 High Price Target$94.00 Low Price Target$77.00 Potential Upside/Downside-8.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E Ratio23.96 P/E GrowthN/ANet Income-$18.52 million Net Margins-1.37% Pretax Margin-1.97% Return on Equity25.03% Return on Assets8.00% Debt Debt-to-Equity Ratio1.39 Current Ratio2.54 Quick Ratio1.96 Sales & Book Value Annual Sales$614.38 million Price / Sales3.27 Cash Flow$7.75 per share Price / Cash Flow11.93 Book Value$20.13 per share Price / Book4.59Miscellaneous Outstanding Shares21,700,000Free Float19,291,000Market Cap$2.01 billion OptionableOptionable Beta0.61 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ANIP) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.